Assessment of Biological and Biometrological Parameters in Adult Subjects with Androgenetic Alopecia
NCT ID: NCT06854432
Last Updated: 2025-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
46 participants
INTERVENTIONAL
2024-03-05
2024-04-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Although it has been shown that testosterone metabolism plays a central role in this pathology, targeting this biological pathway is not fully efficient to treat androgenetic alopecia, suggesting that other factors are involved, notably factors linked to the perifollicular environment. Moreover, the very specific pattern of androgenetic alopecia is not yet fully understood: the occipital and lower temporal areas of the scalp are always preserved. Once the hair follicle has disappeared, it is not possible to make it grow back, it is then important to provide a treatment that slows down the progression of androgenetic alopecia at the earliest stage of the pathology, and that specifically targets the affected area.
The aim of this study is to better understand androgenetic alopecia pathophysiology by a multi-omic approaches and biometrological analysis, in the same study, on the local ecosystem of bald scalp areas and non-bald scalp areas of adult with androgenetic alopecia, compared to scalp of adult without androgenetic alopecia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacogenomic Study of Androgenetic Alopecia
NCT01227031
Assessment of the Effects and Tolerance of the RV4986A Lotion in Men With AGA After Hair Transplant
NCT06576492
Efficacy Study of Cosmetic Product Against Telogen Effluvium on Women
NCT04652232
Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia
NCT02154503
Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia
NCT01286649
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control subject group
Biometrological measurements
Measurements will be taken from the scalp: on the vertex and occiput areas.
Biological sampling
Samples will be taken from the scalp: on the vertex and occiput areas.
Subject group with androgenetic alopecia
Biometrological measurements
Measurements will be taken from the scalp: on the vertex and occiput areas.
Biological sampling
Samples will be taken from the scalp: on the vertex and occiput areas.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biometrological measurements
Measurements will be taken from the scalp: on the vertex and occiput areas.
Biological sampling
Samples will be taken from the scalp: on the vertex and occiput areas.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject having received on study areas artificial UV exposure, excessive or prolonged exposure to natural sunlight between selection and inclusion visit
Criteria related to the disease:
• Subject with any adverse event occurring between selection and inclusion visit liable to interfere with the study assessments
Criteria related to treatments and/or products:
• Any procedures, treatments, products and/or hair care taken, applied or performed between selection and inclusion visit liable to interfere with the study assessments
30 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pierre Fabre Dermo Cosmetique
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Skin Research Center
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INTERALOPECIE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.